Novo Nordisk: Commercialising stem cells

January 2010. Stem cell applications require other business models than those based on pharmacological treatments. What is the approach of Novo Nordisk compared with competitors like Eli Lilly, Pfizer, or Eli Lilly, Sanofi-Aventis? Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk in the interview with B2Bioworld.Reading time: 10 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section